Abstract
Objective
To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor (G-CSF) in breast cancer patients.
Methods
A total of 57 breast cancer patients were treated with docetaxel 120 mg/m2. When the white blood cell (WBC) count decreased to 1.0×109/L, patients were given G-CSF 5 μg/kg daily by subcutaneous injection until the end of apheresis. Peripheral blood mononuclear cells (MNC) were isolated by Cobe Spectra Apheresis System. The percentage of CD34+ cell was assayed by flow cytometry.
Results
At a median 6 of days (range 3–8) after the administration of docetaxel, the median WBC count decreased to 1.08×109/L (range 0.20–2.31). The median duration of G-CSF mobilization was 3 days (range 2–7). The MNC collection was conducted 8–12 days (median 10 days) after docetaxel treatment. The median MNC was 5.35×108/kg (range 0.59–14.07), the median CD34+ cell count was 2.43×106/kg (range 0.16–16.69). The CD34+ cell count was higher than 1.00×106/kg in 47 of 57 cases (82.46%) and higher than 2.00×106/kg in 36 cases (63.16%). The CD34+ cell count was higher than 2.00×106/kg in 27 collections (23.68%). The MNC count and the CD34+ cell count were correlated with the bottom of WBC after docetaxel chemotherapy (r=0.364, 0.502, P=0.005, 0.000). The CD34+ cell count was correlated with the MNC count (r=0.597, P=0.000). The mobilization and apheresis were well tolerated in all patients. Mild perioral numbness and numbness of hand or feet were observed in 3 cases. No serious adverse events were reported.
Conclusion
Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gluz O, Nitz UA, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 2008; 19:861–870.
Zander AR, Schmoor C, Kröger N, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol 2008; 19:1082–1089.
Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005; 366:1935–1944.
Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431–1439.
Stadtmauer EA, Schneider CJ, Silberstein LE. Peripheral blood progenitor cell generation and harvesting. Semin Oncol 1995; 22: 291–300.
Gómez-Espuch J, Moraleda JM, Ortuño F, et al. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF. Bone Marrow Transplant 2000; 25:231–235.
Weaver CH, Schwartzberg LS, Birch R, et al. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer. Biol Blood Marrow Transplant 1997; 3:83–90.
Burris HA 3rd. Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 1999; 26:1–6.
Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212–1219.
O’shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812–2823.
Gorin NC. Collection, manipulation and freezing of haemopoietic stem cells. Clin Haematol 1986; 15:19–48.
Ikeda K, Kozuka T, Harada M. Factors for PBPC collection efficiency and collection predictors. Transfus Apher Sci 2004; 31:245–259.
DeLuca E, Sheridan WP, Watson D, et al. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 1992; 66:893–899.
Teshima T, Harada M, Takamatsu Y, et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992; 10:215–220.
Imamura R, Miyamoto T, Yoshimoto G, et al. Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor. J Immunol 2005; 175:2647–2654.
Dührsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72:2074–2081.
To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997; 89:2233–2258.
Burtness BA, Psyrri A, Rose M, et al. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplant 1999; 23:311–315.
Baur M, van Oosterom AT, Diéras V, et al. A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol, 2008, 134:125–135.
Prince HM, Toner GC, Seymour JF, et al. Docetaxel effectively mobilizes peripheral blood CD34+ cells. Bone Marrow Tansplant 2000; 26: 483–487.
Laport GG, Fleming GF, Waggoner S, et al. A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant 2001; 27: 677–681.
Fleming DR, Goldsmith J, Goldsmith GH, et al. Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel. J Hematother Stem Cell Res 2000; 9:855–860.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a grant from the Beijing Capital Development Foundation for Medical Sciences (No. 2007-2053).
Rights and permissions
About this article
Cite this article
Yu, J., Ren, J., Di, Lj. et al. Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients. Chin. J. Cancer Res. 23, 49–53 (2011). https://doi.org/10.1007/s11670-011-0049-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11670-011-0049-8